Gut Bacteria Differ by Heart Valve Disease, Study Finds

If you or someone you love has been told a heart valve is stiffening or leaking, the explanation usually stops at aging, genetics, or cholesterol. A new study adds a less familiar suspect to that list: the trillions of bacteria living in the gut. Researchers comparing patients with two different valve conditions found their gut microbiomes look distinctly different from one another, not just from a generic "healthy" baseline, suggesting the gut may be quietly tracking the specific type of heart disease a person has.

Key takeaways:

• In a study of 122 heart valve patients, gut bacteria composition clearly separated aortic stenosis (a stiffened, narrowed valve) from aortic regurgitation (a leaking valve), even though the two groups were closely matched on age, weight, and other health markers.
• Aortic stenosis patients had an unusually tight, interconnected network of gut bacteria, built around Bacteroides, Alistipes, Parabacteroides, and Faecalibacterium working as a correlated cluster rather than scattered individual changes.
• This is a snapshot in time, not proof the bacteria cause valve disease, and the study had no healthy comparison group, so it cannot yet say whether these bacterial patterns are unique to valve disease or reflect broader illness.

Aortic Stenosis Patients Carry a Distinct Gut Bacterial Signature

Patients with aortic stenosis, a narrowing of the heart's aortic valve that restricts blood flow, had a measurably different gut bacterial makeup than patients with aortic regurgitation, a leaky version of the same valve that lets blood flow backward. Researchers at the University Hospital Bonn in Germany, publishing their findings in a study in Scientific Reports, swabbed the rectums of 122 patients undergoing heart valve surgery and sequenced the bacterial DNA present (a technique called 16S rRNA gene sequencing, which identifies which bacterial species are present and in what proportions). Using a statistical measure of community-level difference called beta diversity, they found aortic stenosis patients and aortic regurgitation patients clustered into separate, largely non-overlapping groups, and that separation held up even after accounting for differences in kidney function, diabetes, and other clinical factors between the groups.

The species doing the separating were notable. Aortic regurgitation patients had higher levels of Bacteroides, Faecalibacterium, Lachnoclostridium, and Alistipes, a mix of bacteria previously linked to lower gut inflammation and, in some cases, protection against artery hardening. Aortic stenosis patients instead ran higher in Corynebacterium, Anaerococcus, Peptoniphilus, and Finegoldia, several of which have shown up in other research on coronary artery disease and inflammation.

What This Means for People With Valve Disease

Aortic stenosis affects a large share of older adults and is currently only fixable through valve replacement surgery or a catheter-based procedure once it becomes severe. There is no approved drug that slows its progression. That gap is exactly why researchers are hunting for biological signals, like a gut bacteria fingerprint, that might one day flag risk earlier or reveal a new treatment target. The study also included a form of the disease called bicuspid aortic stenosis, where the valve has two flaps instead of the usual three from birth and tends to cause problems decades earlier than the standard three-flap version. Bicuspid and standard (tricuspid) stenosis patients had nearly identical gut bacteria profiles to each other, both diverging from the leaky-valve group in the same direction, which suggests the signal tracks with the stenosis disease process itself rather than with valve anatomy.

How Researchers Compared 122 Heart Valve Patients' Gut Microbes

The study's key methodological choice was its comparison group. Rather than comparing valve disease patients only to broadly healthy people, the researchers used aortic regurgitation patients, who also have valve disease and undergo similar heart surgery, as the control group. That matters because it strips out a lot of the noise that comes from simply being a cardiac surgery patient (hospital diet, medications, general cardiovascular risk) and isolates what is specific to stenosis. The final cohort included 33 aortic regurgitation patients, 22 bicuspid stenosis patients, and 67 tricuspid stenosis patients, and the three groups were statistically similar on age, sex, smoking history, blood pressure, and metabolic markers like cholesterol and blood sugar. The researchers also ran a separate statistical test (redundancy analysis) to check whether age, diabetes, obesity, or blood lipids could explain the microbiome differences, and found only a weak link to blood lipids, reinforcing that the split tracked with valve disease type rather than these usual suspects.

Beyond looking at individual bacteria, the team mapped how species co-occur in clusters, an approach called co-abundance network analysis. In aortic regurgitation patients, that network was loose, centered on just two bacterial genera each linked to a handful of others. In aortic stenosis patients, by contrast, the researchers found a much tighter web: Bacteroides, Alistipes, Parabacteroides, and Faecalibacterium were all significantly correlated with each other and with at least three other bacterial types apiece, forming what the authors describe as a highly interconnected hub. That distinction, a diffuse network versus a dense one, is a more elaborate pattern than "bacteria X is up, bacteria Y is down," and hints that entire microbial communities may shift together in disease rather than single species acting alone.

What to Watch For If You Have Aortic Valve Disease

None of this changes how aortic stenosis or regurgitation is currently diagnosed or treated, and the study does not test any probiotic, diet, or supplement. What it does offer is a plausible mechanism worth knowing about: some of the bacteria linked to aortic stenosis in this study, including Peptoniphilus and Fusobacterium species, have separately been tied to inflammation and coronary artery disease in other research, while bacteria enriched in the regurgitation group, like Bacteroides, have been linked in other work to lower gut-derived inflammation and reduced artery hardening (see the related atherosclerosis research below). If you are managing valve disease, this is a reason to keep discussing gut health and inflammation with your cardiologist as the science develops, not a signal to start any specific bacterial supplement, since none has been tested for this purpose.

Why This Study Can't Prove Cause and Effect Yet

The study has three significant limits the authors themselves flag. First, it is cross-sectional, meaning bacteria and valve disease were measured at a single point in time, so the study can show correlation but not which came first or whether one causes the other. Second, there was no healthy control group with no valve disease at all, only a comparison between two different valve conditions, so it remains unclear whether the aortic stenosis bacterial signature is truly specific to that disease or reflects something more general about being sick or hospitalized. Third, while the researchers tried to match the groups on clinical factors, patients with stenosis and regurgitation are not perfectly comparable diseases, and some differences, like slightly worse kidney function in the regurgitation group, could not be fully controlled for. The authors also note a related biological pathway worth watching: gut bacteria can produce a compound called trimethylamine N-oxide (TMAO), which other research has linked to aortic stenosis severity and worse outcomes after valve procedures, though this study did not directly measure TMAO levels in its patients.

What Comes Next for Microbiome-Targeted Heart Valve Research

The authors call for two clear next steps: longitudinal studies that track the same patients' gut bacteria over time to see whether microbiome changes precede valve deterioration, and animal studies that deliberately alter levels of the standout bacteria, particularly Bacteroides, Parabacteroides, and Faecalibacterium, to test whether that changes disease progression rather than just correlates with it. No timeline for either was given, and any therapeutic application, such as a probiotic or dietary intervention targeting these specific bacteria, remains purely speculative until those studies are done.

Common Questions

Does this mean probiotics can treat aortic stenosis? No. The study did not test any probiotic or supplement, and no such treatment has been proven to affect valve disease. The bacteria identified are markers found alongside the disease, not a demonstrated cure or preventive measure.

Why did researchers use aortic regurgitation patients instead of healthy people as the comparison group? Using another valve disease group controls for factors like being a cardiac surgery patient, similar medications, and hospital diet, isolating what is specific to the narrowing (stenosis) process. The tradeoff is that without a healthy control group, it is unclear whether these bacterial patterns are unique to stenosis or common to valve disease broadly.

Is bicuspid aortic stenosis, which starts younger, linked to different gut bacteria than the more common form? No, the study found bicuspid and tricuspid (three-flap) aortic stenosis patients had nearly identical gut bacteria profiles, both differing from aortic regurgitation patients in the same direction, suggesting the microbiome pattern tracks with the stenosis disease process rather than the valve's underlying anatomy.

What is a gut bacteria co-abundance network, and why does it matter here? It is a map of which bacterial species rise and fall together rather than independently. Aortic stenosis patients showed a tightly interconnected cluster of bacteria, while regurgitation patients showed a looser one, suggesting whole bacterial communities, not single species, may shift together during valve disease.

References

1. Benedikt Bartsch, Svetozar Nesic, Muntadher Al Zaidi, et al. (2026). Gut microbiome composition differs between aortic stenosis and aortic regurgitation patients. Scientific Reports. https://doi.org/10.1038/s41598-026-63354-w
2. Naofumi Yoshida, Tomoya Yamashita, Shigenobu Kishino, et al. (2020). A possible beneficial effect of Bacteroides on faecal lipopolysaccharide activity and cardiovascular diseases. Scientific Reports. https://doi.org/10.1038/s41598-020-69983-z
3. Yuchao Guo, Shaojun Xu, Hong Zhan, et al. (2023). Trimethylamine N-Oxide Levels Are Associated with Severe Aortic Stenosis and Predict Long-Term Adverse Outcome. Journal of Clinical Medicine. https://doi.org/10.3390/jcm12020407